Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Roger Wrigglesworth is active.

Publication


Featured researches published by Roger Wrigglesworth.


Tetrahedron | 2003

Novel series of 8H-quinazolino[4,3-b]quinazolin-8-ones via two Niementowski condensations

Francois-Rene Alexandre; Amaya Berecibar; Roger Wrigglesworth; Thierry Besson

Efficient microwave-assisted multi-step synthesis of 8H-quinazolino[4,3-b]quinazolin-8-one was investigated. The synthesis involved two Niementowski condensations from anthranilic acids. Homogeneous or heterogeneous conditions were studied with the aim to develop convenient syntheses of the desired compounds.


Tetrahedron Letters | 2003

Efficient synthesis of thiazoloquinazolinone derivatives

Francois-Rene Alexandre; Amaya Berecibar; Roger Wrigglesworth; Thierry Besson

An original route to the rare 8H-thiazolo[5,4-f]quinazolin-9-one 1 and the novel 7H-thiazolo[4,5-h]quinazolin-6-one 2 is described. Access to the regioisomers was realized by fusion of a thiazole and a quinazoline ring via Appels salt chemistry. Thermal reactions were carried out using a focused microwave reactor, reducing the overall time of the multi-step synthesis.


Bioorganic & Medicinal Chemistry Letters | 2011

Thiophene and bioisostere derivatives as new MMP12 inhibitors.

Matthew Badland; Delphine Compere; Karine Courte; Anne-Claude Dublanchet; Stéphane Blais; Ajith C. Manage; Guillaume Peron; Roger Wrigglesworth

A new MMP12 inhibitor series has been identified containing a thiophene moiety. Different approaches have been considered to replace this potential toxicophore. α-Fluorothiophene derivatives were the most interesting compounds. Their synthesis is presented.


Journal of Computer-aided Molecular Design | 2001

CoMFA and CoMSIA 3D-quantitative structure-activity relationship model on benzodiazepine derivatives, inhibitors of phosphodiesterase IV.

Pierre Ducrot; Charles Andrianjara; Roger Wrigglesworth

Recently, we reported structurally novel PDE4 inhibitors based on 1,4-benzodiazepine derivatives. The main interest in developing bezodiazepine-based PDE4 inhibitors is in their lack of adverse effects of emesis with respect to rolipram-like compounds. A large effort has thus been made toward the structural optimization of this series. In the absence of structural information on the inhibitor binding mode into the PDE4 active site, 2D-QSAR (H-QSAR) and two 3D-QSAR (CoMFA and CoMSIA) methods were applied to improve our understanding of the molecular mechanism controlling the PDE4 affinity of the benzodiazepine derivatives. As expected, the CoMSIA 3D contour maps have provided more information on the benzodiazepine interaction mode with the PDE4 active site whereas CoMFA has built the best tool for activity prediction. The 2D pharmacophoric model derived from CoMSIA fields is consistent with the crystal structure of the PDE4 active site reported recently. The combination of the 2D and 3D-QSAR models was used not only to predict new compounds from the structural optimization process, but also to screen a large library of bezodiazepine derivatives.


Bioorganic & Medicinal Chemistry Letters | 2004

Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: Design, synthesis and structure–activity relationship studies

Fabrice Vergne; Patrick Bernardelli; Edwige Lorthiois; Nga Pham; Emmanuelle Proust; Chrystelle Oliveira; Abdel-Kader Mafroud; Frederique Royer; Roger Wrigglesworth; Jennifer K. Schellhaas; Mark Robert Barvian; François Moreau; Moulay Idrissi; Anita Tertre; Bernadette Bertin; Magali Coupe; Patrick Berna; Patricia Soulard


Bioorganic & Medicinal Chemistry Letters | 2004

Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1

Edwige Lorthiois; Patrick Bernardelli; Fabrice Vergne; Chrystelle Oliveira; Abdel-Kader Mafroud; Emmanuelle Proust; Lamia Heuze; François Moreau; Moulay Idrissi; Anita Tertre; Bernadette Bertin; Magali Coupe; Roger Wrigglesworth; Arnaud Descours; Patricia Soulard; Patrick Berna


Bioorganic & Medicinal Chemistry Letters | 2004

Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: Metabolism-directed optimization studies towards orally bioavailable derivatives

Fabrice Vergne; Patrick Bernardelli; Edwige Lorthiois; Nga Pham; Emmanuelle Proust; Chrystelle Oliveira; Abdel-Kader Mafroud; Pierre Ducrot; Roger Wrigglesworth; Françoise Berlioz-Seux; Francis Coleon; Eric Chevalier; François Moreau; Moulay Idrissi; Anita Tertre; Arnaud Descours; Patrick Berna; Mei Li


Tetrahedron | 2005

Synthesis of novel 1,3,4-benzotriazepine derivatives from 4-oxo-3,1-benzoxazine and 3,1-benzothiazine-2-carbonitriles

Francois-Rene Alexandre; Amaya Berecibar; Roger Wrigglesworth; Laurence Perreux; Jean Guillon; Jean-Michel Leger; Valérie Thiéry; Thierry Besson


Tetrahedron-asymmetry | 2004

Resolution of trans-3-aminocyclohexanol

Patrick Bernardelli; Michael Bladon; Edwige Lorthiois; Ajith C Manage; Fabrice Vergne; Roger Wrigglesworth


Bioorganic & Medicinal Chemistry Letters | 2004

New substituted triaza-benzo[ cd ]azulen-9-ones as promising phosphodiesterase-4 inhibitors

Ingrid Devillers; Isabelle Pevet; Henry Jacobelli; Corinne Durand; Veronique Fasquelle; Jocelyne Puaud; Bernard Gaudilliere; Moulay Idrissi; François Moreau; Roger Wrigglesworth

Collaboration


Dive into the Roger Wrigglesworth's collaboration.

Researchain Logo
Decentralizing Knowledge